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Alzheimer’s disease (AD) is the most common neurodegenerative disorder characterized
by progressive cognitive decline leading to dementia. The amyloid precursor protein
(APP) is a ubiquitous type I transmembrane (TM) protein sequentially processed to
generate the β-amyloid peptide (Aβ), the major constituent of senile plaques that are
typical AD lesions. There is a growing body of evidence that soluble Aβ oligomers
correlate with clinical symptoms associated with the disease. The Aβ sequence begins
in the extracellular juxtamembrane region of APP and includes roughly half of the
TM domain. This region contains GXXXG and GXXXA motifs, which are critical for
both TM protein interactions and fibrillogenic properties of peptides derived from TM
α-helices. Glycine-to-leucine mutations of these motifs were previously shown to affect
APP processing and Aβ production in cells. However, the detailed contribution of
these motifs to APP dimerization, their relation to processing, and the conformational
changes they can induce within Aβ species remains undefined. Here, we describe
highly resistant Aβ42 oligomers that are produced in cellular membrane compartments.
They are formed in cells by processing of the APP amyloidogenic C-terminal fragment
(C99), or by direct expression of a peptide corresponding to Aβ42, but not to Aβ40.
By a point-mutation approach, we demonstrate that glycine-to-leucine mutations in the
G29XXXG33 and G38XXXA42 motifs dramatically affect the Aβ oligomerization process.
G33 and G38 in these motifs are specifically involved in Aβ oligomerization; the G33L
mutation strongly promotes oligomerization, while G38L blocks it with a dominant
effect on G33 residue modification. Finally, we report that the secreted Aβ42 oligomers
display pathological properties consistent with their suggested role in AD, but do not
induce toxicity in survival assays with neuronal cells. Exposure of neurons to these
Aβ42 oligomers dramatically affects neuronal differentiation and, consequently, neuronal
network maturation.
Keywords: Alzheimer’s disease, amyloid precursor protein, beta-amyloid peptide, oligomers, GXXXG motifs,
neuronal differentiation
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INTRODUCTION
The amyloid precursor protein (APP) is a ubiquitously expressed
type 1 transmembrane protein (Kang et al., 1987; Selkoe, 2004)
whose processing in the amyloidogenic pathway leads to the
production of the β-amyloid peptides (Aβ). Aβ peptides are
the major constituent of the senile plaques, a hallmark of
AD (Glenner and Wong, 1984). Mutations responsible for
inherited AD cases (early onset or familial AD) are located
in the genes coding for APP or the presenilins (Kandimalla
et al., 2012). The presenilins (PS1 and PS2) are the catalytic
subunits of γ-secretase, a multiprotein complex that cleaves
the APP β-C-terminal fragment (βCTF or C99) to generate
Aβ in the last step of the amyloidogenic pathway. APP or PS
mutations typically result in imbalanced Aβ production and an
increased Aβ42/Aβ40 ratio (Selkoe, 2004). These observations
led to the amyloid cascade hypothesis, predicting that the initial
steps of AD, which trigger a series of pathogenic events, are
related to Aβ production and clearance (Hardy and Allsop,
1991). Although this hypothesis remains a matter of debate
(Herrup, 2015), experimental lines of evidence from cellular
models, transgenic animals and patient brain samples has been
overwhelming (Hardy, 2009). Less is known about the cellular
mechanisms that control the formation of pathological Aβ
oligomers. Both cellular trafficking, particularly endocytosis, and
posttranslational modification like phosphorylation have been
involved in Aβ production and accumulation (Feyt et al., 2005,
2007).
Alzheimer’s disease onset and progression appears to be
directly linked to the accumulation of abnormally folded Aβ
assemblies. Although fibrillogenic species were first suggested
to be responsible for AD-induced neurotoxic events, growing
evidence shows that soluble Aβ oligomers are more strongly
correlated with clinical symptoms associated with the disease
(Lesne et al., 2006; McDonald et al., 2010; Kandimalla et al.,
2011, 2014). Different Aβ oligomers have been described,
ranging from dimers to dodecamers and high molecular weight
assemblies. These assemblies can be classified between an “off-
pathway” or an “on-pathway” with respect to fibrillization.
Soluble oligomers have been characterized in transgenic mouse
brains (Kawarabayashi et al., 2001; Lesne et al., 2006; Shankar
et al., 2009; Pham et al., 2010), and to some extent in brains
of AD patients (Hayden and Teplow, 2013). Still, the key toxic
Aβ species remain poorly defined in terms of both molecular
structure and relevance to the mechanisms underlying long term
potentiation defects and neuronal cell death.
Structural studies on Aβ assemblies have largely come from
in vitro measurements of synthetic peptides corresponding to
Aβ40 and Aβ42. Aβ40 is the predominant isoform (∼90%)
generated by γ-secretase cleavage, while Aβ42 (10%) is the
major component of amyloid plaques. Monomeric Aβ adopts
predominantly a random coil structure. Monomers associate
into small MW oligomers (dimers – hexamers) that are able
to combine into larger MW oligomers, which in turn laterally
associate into protofibrils (Fu et al., 2015). The conversion of
protofibrils to fibrils involves a transition to cross-β-structure.
The conversion implies association of the short hydrophobic
LVFF sequence with the hydrophobic C-terminus of Aβ (Fu et al.,
2015).
Glycines appear to be important in both the turn region
between β-strands and in the C-terminal β-sheet. Glycines have a
critical impact on peptide aggregation, facilitating the association
of β-sheets during fibril formation in vitro (Liu et al., 2005; Sato
et al., 2006). Fibrillization of synthetic Aβ peptides containing
glycine-to-leucine (G to L) mutations has been monitored
in vitro (Kim and Hecht, 2006; Hung et al., 2008). Treatment
of neuronal cells showed a reduction of toxicity for mutated
peptides when compared to non-mutated Aβ. Reduced toxicity
correlated with a reduction of small oligomeric species in solution
and increased rates of fibril formation (Hung et al., 2008). Using
synthetic peptides, Harmeier et al. (2009) highlighted G33 as
critical for the generation of Aβ42 assemblies. Mutation of G33
promoted rapid Aβ oligomerization by conformational changes
that favored the formation of high molecular weight oligomers,
which were less pathogenic than Aβ42. In contrast, a G37L
substitution dramatically reduced Aβ toxicity as measured by cell
dysfunction, cell death, synaptic alteration in primary neurons
and transgenic Caenorhabditis elegans models (Fonte et al., 2011).
Important limitations in studies using synthetic Aβ peptides
to generate oligomers in vitro are their exact relevance to AD
pathology. The soluble oligomers are formed in vitro at relatively
high concentrations. At lower concentrations, which may be
more representative of physiological conditions, the monomer –
oligomer equilibrium shifts toward the monomeric state, which
is non-toxic and presumably is more easily cleared from the
brain. The structure and stability of soluble oligomers that are
produced physiologically have consequently been of considerable
interest.
G33 and G37 lie within the hydrophobic C-terminus of
the Aβ peptide and represent the third APP TM GXXXG
motif. GXXXG motifs occur abundantly in the TM helices of
membrane proteins where they facilitate TM helix dimerization
and close apposition. Strikingly, C99 has three consecutive
GXXXG motifs, followed by a GXXXA motif, all of which
have been implicated in dimerization and regulation of C99
processing by the γ-secretase complex (Munter et al., 2007;
Kienlen-Campard et al., 2008). The structural role that the
GXXXG motif plays critically depends on the structural element
in which it is located and the exposure to water. In aqueous
environments, glycine is able to adopt multiple conformations
due to the lack of a side chain and the ability of the backbone
NH to hydrogen bond to water (glycine is known as a helix
breaker in soluble proteins and often occurs in turn sequences).
In hydrophobic TM helices, glycines in a GXXXG motif fall on
one face of a TM α-helix and facilitate helix-helix dimerization.
The TM helices are energetically favored due to intrahelical
backbone hydrogen bonding in the absence of water and helix
association is favored due to interhelical van der Waals and
hydrogen bonding interactions. Interestingly, in β-sheets the
glycines in a GXXXG motif lie on one face of the β-sheet
and when the β-strands are parallel and in-register, they form
long surface grooves that facilitate sheet-to-sheet packing that
excludes water (Sato et al., 2006). This multifaceted nature of
glycine is highlighted in its role at each stage of the process from
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TM helix to soluble oligomer to fibril. The same multifaceted
nature of glycine may underlie the aggregation of the human
prion protein, which also contains three consecutive GXXXG
motifs.
We have further investigated the role of the GXXXG/GXXXA
motifs in dimerization of C99 and oligomerization of Aβ
produced by living cells. We found that mutation of the critical
G33 and G38 residues, respectively, in the G29XXXG33 and
G38XXXA42 motifs did not affect dimerization of C99. In
contrast, mutations in these motifs triggered the assembly of
Aβ42, in living cells, into ∼28 kDa oligomers corresponding
to the expected molecular weight of Aβ hexamers. Similar
oligomers are not detected with constructs producing only
Aβ40. The Aβ42 oligomers generated by living cells are resistant
to temperature and denaturing conditions. They are enriched
in membrane-bounded compartments, and released in the
extracellular medium. Finally, we showed that Aβ42 oligomers
generated by living cells did not display neurotoxic effects, but
greatly affected neuronal differentiation and the formation of
neuronal networks.
MATERIALS AND METHODS
Chemicals and Reagents
Restriction enzymes, Taq DNA polymerase, all culture media,
penicillin-streptomycin solution, HAT and Lipofectamine R©
transfection reagents, Nu-Page R© Novex R© 4–12% Bis-Tris
gels and buffers were from Life Technology Corporation
(Carlsbad, CA, USA). Fetal bovine serum (FBS) for culture
media was purchased from Thermo Scientific (Rockford, IL,
USA). Analytical grade solvents, salts and poly-L-lysine were
from Sigma–Aldrich (St Louis, MO, USA). Protease inhibitor
cocktail was purchased from Roche (Basel, Switzerland).
BCA protein assay kit was from Pierce (Rockford, IL, USA).
Nitrocellulose membranes were obtained from GE Healthcare
(Fairfield, CT, USA). ECL reagents were obtained from
Perkin Elmer Inc. (Waltham, MA, USA). The following
primary antibodies were used: anti-Amyloid β Antibody, clone
W0-2 (EMD Millipore, Billerica, MA, USA), Anti-Amyloid
Precursor Protein C-terminal, anti-MAP2 and anti-actin
antibody (Sigma–Aldrich, St Louis, MO, USA), and anti-
GLuc antibody (New England Biolabs, Ipswich, MA, USA).
Fluorescent nucleic acid stain DAPI was obtained from Sigma–
Aldrich (St Louis, MO, USA). Secondary antibodies coupled
to HRP were obtained from Amersham Bioscience (Uppsala,
Sweden) and fluorescent secondary antibody coupled to Alexa
fluorochromes from Life Technology Corporation (Carlsbad,
CA, USA).
Cells Lines and Cell Culture
Chinese hamster ovary (CHO) cell lines were grown in
Ham’s F-12 medium. The media was supplemented with
10% of FBS and penicillin-streptomycin solution (10 units–
10 µg). All cell cultures were maintained at 37◦C in a
humidified atmosphere (5% CO2). Mouse neuroblastoma × Rat
glioma hybrid cell lines (NG108-15) were grown in DMEM
supplemented with 10% FBS, 2% HAT, a mixture of
hypoxanthine, aminopterin and thymidine, and antibiotics.
Differentiation of NG108-15 cells was induced by switching
from regular medium to 1% FBS medium (Stanga et al.,
2015).
Plasmids, Cloning, and Site-Directed
Mutagenesis
C99, C42 mutants and various C-terminally truncated constructs
of C99 were obtained by Quick-change site-specific mutagenesis
(Stratagene, La Jolla, CA, USA) as previously described (Ben
et al., 2012b). The plasmids expressing APP fragments fused
to humanized Gaussia luciferase (hGluc) halves were obtained
by PCR amplification of APP sequences encoded by expression
vectors previously described (Decock et al., 2015). All constructs
were verified by full sequencing (Macrogen Europe, Amsterdam,
The Netherlands).
Cell Transfection and Conditioning
Chinese hamster ovary cells were transfected with Lipofectamin
reagent 24 h after seeding following manufacturer’s instructions.
Plasmids expressing the split-luciferase proteins were
cotransfected in a 1:1 ratio. The control plasmid (mock)
used was the corresponding empty vector. 48 h after transfection,
media were collected, treated with protease inhibitors cocktail
(Roche) and stored at −20◦C for ECLIA assay. Cells were
harvested and lysed in sample buffer (125 mM TrisHCl pH
6.8, glycerol 20% and SDS 4%) supplemented with protease
inhibitor cocktail. Protein concentrations were measured by the
BCA protein assay kit from Pierce (Rockford, IL, USA) prior to
Western blotting.
Transfected CHO cell culture media have been used as
source of oligomers to treat NG108-15 cells at days 1 and 3
of differentiation. One day after transfection, CHO cells were
maintained in medium without FBS. The CHO conditioned
media enriched in oligomers were mixed (1:1 ratio) to NG108-
15 cells differentiation medium (1% FBS). Treated NG108-
15 cells were fixed and processed for immunocytochemistry
(day 5).
Western Blotting
Proteins (10 µg) from cell lysates or culture media (20 µl)
were heated for 10 min at 70◦C in loading buffer (lysis buffer
supplemented with 0.5 M DTT and staining Nupage blueTM),
separated in 4–12% NupageTM bis-Tris gel and transferred
for 2 h at 30 V onto nitrocellulose membranes. Ponceau Red
staining was used to check gel loading and transfer accuracy.
After blocking (5% non-fat milk in PBS), membranes were
incubated overnight at 4◦C with the primary antibodies: anti-
Amyloid β Antibody, clone W0-2 (1/2,500), Anti-Amyloid
Precursor Protein, C-terminal antibody (1/2,000), anti-GLuc
antibody (1/2,000). Membranes were washed with PBS-Tween
(0.005%) and incubated with the secondary antibodies anti-
mouse (1:10,000) or anti-rabbit (1:10,000) coupled to peroxidase
prior to ECL detection from GE Healthcare (Little Chalfont, UK).
Signals were quantified with a Gel Doc 2000 imaging system
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coupled to Quantity oneTM software from Bio-Rad (Hercules,
CA, USA).
Gaussia Luciferase Assay
Samples were aliquoted in 5 ml polystyrene round-bottom
tubes at a final concentration of 10 µg of protein in
20 µl in Luciferase Cell Lysis Buffer (Promega, Madison,
WI, USA). Native coelenterazine was reconstituted as a
stock solution of 1 mg/ml in methanol (stored frozen),
diluted 30 min prior reading in DMEM without phenol red
and used at a final concentration of 20 µM. 50 µl of
coelenterazine was added to tubes and luminescence directly
measured on a Sirius Luminometer (Berthold, Pforzheim,
Germany).
Aβ Quantification
Aβ38, Aβ40, and Aβ42 peptides were quantified in the cell
medium as previously described (Hage et al., 2015) using the
Aβ multiplex electro-chemiluminescence immunoassay (ECLIA;
Meso Scale Discovery, Gaithersburg, MD, USA). Cells were
conditioned in serum-free medium for 16 h; cell medium was
collected and Aβ were quantified according to the manufacturer’s
instructions with the human Aβ specific 6E10 multiplex
assay.
Cell Survival Assay
Cell viability (NG108-15 cells) was assessed with a MTS
assay after 24 h of treatment, according to manufacturer’s
instruction (Promega, Madison, WI, USA). Plates were measured
at 490 nm using a microplate spectrophotometer Victor
X3 Multilabel Plate Reader (PerkinElmer, Waltham, MA,
USA).
Immunocytochemistry
Cells were seeded on 12-well plates previously incubated with
poly-L-lysine (10 mg/ml). Prior to staining, cells were rinsed
twice with Opti-MEM R© (Life Technology Corporation) and
fixed with 4% paraformaldehyde (PFA) for 15 min. After three
washes in PBS, cells were permeabilized with PBS1X/0.3%
Triton100X for 30 min and blocked in PBS1X/fetal bovine
serum 5%/0.1% Triton100X for 30 min. Primary antibody MAP2
(1:500) was prepared in the blocking solution and incubated
O/N at 4◦C. After three washes in PBS, cells were incubated
with secondary antibody (Goat anti-mouse Alexa 488, 1:500
in blocking solution) and DAPI (1:2000) for 1 h at 4◦C.
After three washes in PBS, cells were stored in PBS-azide
0.1% at 4◦C. Pictures were acquired with an Evos fluorescence
microscope (Advanced Microscopy Group, Mill Creek, WA,
USA).
Statistical Analysis
The number of samples (n) in each experimental condition
is indicated in figure legends. The data were analyzed using
GraphPad Prism software by analysis of variance (ANOVA)
followed by unpaired t-test (two experimental conditions) or
by Bonferroni’s Multiple Comparison tests (more than two
experimental conditions).
RESULTS
Expression of APP C-Terminal
Fragments Leads to the Accumulation of
Oligomeric Aβ Peptides
In our previous work we reported that expression of C99
(corresponding to the β-CTF of APP) leads to the formation of
an oligomer, which is detected in denaturating gels as a higher
molecular weight band (around 25 kDa). This band was thought
to contain dimers of C99 (Kienlen-Campard et al., 2008), but also
-possibly- oligomers of Aβ or other peptides, as well as a mix of
C99 and truncated C99 peptides.
In order to characterize the nature of this higher molecular
weight band, we expressed in CHO cells different APP
constructs: human APP695 (neuronal isoform of APP), C99 (the
amyloidogenic β C-terminal stub) and C42, which corresponds
to the sequence of human Aβ42, that we engineered by adding a
stop codon after residue 42 of Aβ. Both C99 and C42 are fused to
the APP signal peptide to ensure proper targeting to the secretory
pathway. Similar constructs were generated by introducing a
stop codon after residue 40 of Aβ to generate C40, or by fusing
Gaussia luciferase moieties to the C-terminus of C99 to measure
its dimerization by a split protein assay (Decock et al., 2015). All
these constructs are depicted in Figure 1.
As previously reported, βCTFs are barely detectable upon
APP expression (Figure 2), the vast majority of APP being
processed by the non-amyloidogenic pathway in cells (Haas
et al., 1995). C99 expression (corresponding to the β-CTF)
led to the detection of a monomeric band and the previously
reported higher molecular weight band (Figure 2A). Strikingly,
C42 expression produced a similar high molecular weight band,
whereas no band corresponding to monomeric C42 was detected
under these conditions. Of note, this higher molecular weight
band was not detected in APP-expressing cell lysates. We
previously suggested (Kienlen-Campard et al., 2008) that this
band could correspond to C99 dimers, but the molecular weight
(∼25–30 kDa) observed here is not consistent with this idea
(Figure 2A). Importantly, the oligomeric band detected was not
recognized by an antibody directed against the APP C-terminus
that recognizes C99 and APP CTFs (Figure 2A). Sub-cellular
fractionation experiments showed that the oligomeric band is
enriched in vesicular compartments (MLP) but barely absent
from the soluble fractions (Figure 2B), strongly suggesting that
the oligomers -like C99- are either membrane associated, or
present in a cell membrane-bounded compartment but not in
the cytosol. The same oligomeric bands were revealed by Western
blotting in the culture medium of cells expressing either C99 or
C42 (Figure 3A), but they were not detectable in the medium of
cells expressing full-length APP. We measured the production of
soluble Aβ in the culture media by the highly sensitive ECLIA
multiplex Aβ assay, which detects soluble Aβ38/Aβ40/Aβ42
monomeric isoforms in the same sample (Hage et al., 2013, 2015).
As previously shown, soluble monomeric Aβwas readily detected
in culture media of APP- and C99-expressing cells, with Aβ40
being the most abundant isoform. C99 constructs produced 3–
5 times more Aβ than full length APP (Figure 3B). Strikingly,
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FIGURE 1 | Schematic representation of the different amyloid precursor protein (APP) mutants and APP constructs used for the study. Schematic
representation of human APP and APP C-terminal fragments including the different mutants generated. Numbering corresponds to the amino acid position in the Aβ
sequence. C99 corresponds to the APP β C-terminal fragment, C42 to the Aβ42 peptide, and C40 to the Aβ40 peptide. All C-terminal constructs are fused to the
human APP signal peptide (SP). TM, Transmembrane region; JM, Juxtamembrane region; AICD, APP IntraCellular Domain; ext, extracellular; int, intracellular. The
amino acid substitutions generated by site-directed mutagenesis are in red. The cleavage sites of α (α)-, β (β)-, and γ (γ and ε)-secretases are indicated by arrows.
C99-hGLuc1 and C99-hGLuc2 correspond to C99 constructs fused to hGLuc moieties used for the analysis of C99 dimerization in split luciferase assays. The
epitopes recognized by the human-specific W0-2 antibody, the APP C-terminal and hGLuc antibodies are indicated.
the C42 construct did not produce detectable Aβ, except very
low amounts of Aβ38. Due to the specificity of the assay (soluble
monomeric Aβ isoforms), this suggested that only oligomeric Aβ
isoforms were generated by C42-expressing cells, in line with the
higher molecular weight bands detected by an anti-human Aβ
antibody in the same media (Figure 3A).
We next investigated whether the oligomeric bands detected
in cells could correspond to oligomeric Aβ recaptured from the
culture medium. We used conditioned media of C42-expressing
cells to treat non-transfected cells for 48 h. Media and cells were
collected and analyzed after treatment (Figure 4). The ∼30 kDa
band was still present in the culture medium after treatment,
indicating its stability. No similar signal was found in the lysates
of treated cells, in contrast to those of C42-expressing cells. This
indicated the oligomers detected were primarily produced in cells
and not recaptured from the culture medium where they are also
present.
Together, these results strongly suggested that the high MW
band could correspond to oligomeric Aβ42 peptides, but did
not formally exclude that they are formed by the assembly of
other Aβ isoforms (e.g., the major Aβ40 isoform) or truncated
APP C-terminal fragments. To test this hypothesis we expressed
C40 constructs in cells, which correspond to the Aβ40 sequence.
C40-expressing cells did not produce the oligomers found in C42-
expressing cells (Supplementary Figure S1). This indicates that
the oligomeric bands observed are produced by Aβ42- but not
Aβ40-expressing constructs. To further confirm this hypothesis,
bands around 30 kDa were excised from gels and subjected to
nano liquid chromatography (nano-LC) coupled to tandem mass
spectrometry (MS/MS). The peptides identified correspond to
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FIGURE 2 | Detection of oligomeric bands in cells expressing C99 and C42. (A) Expression of APP, C99 and C42 in CHO cells analyzed in total cell lysates by
Western blotting with the W0-2 antibody (left panel) and the APP C-terminal antibody (right panel). The presence of APP, βCTF (C99) and αCTF are indicated by
arrows. The star (∗) indicates the presence of an unexpected band at ∼30 kDa. (B) Cell fractions from C42- (left panel) and C99- (right panel) transfected cells were
analyzed by Western blotting with the W0-2 antibody. Total cell lysates (e) were fractionated into soluble (s) and membrane-enriched vesicular fractions (MLP). The
presence of the higher molecular weight band (∗) is indicated by arrows.
human Aβ sequences (Supplementary Figure S2). No other APP
fragments (e.g., from the C-terminus) were identified in these
gel samples, even in C99-expressing cells. Thus, we can conclude
that the oligomers detected in transfected cells are indeed Aβ
oligomers, and more precisely Aβ42 oligomers.
Mutations of Glycine Residues Present in
GXXXG on GXXXA Motifs Are Critical for
the Aβ Oligomerization Process
We previously reported that the oligomeric bands identified here
as Aβ42 oligomers were more abundant using C99 constructs
mutated in the GXXXG motifs (Kienlen-Campard et al., 2008).
In our initial hypothesis, GXXXG mutations induced rotations
in the TM helical regions that form stable associations through
the GXXXA interface, strengthening dimerization of the APP
transmembrane domain (TMD). We mutated the glycine and
alanine residues within the G29XXXG33/G38XXXA42 motifs
(Figure 5A) to study their contribution to C99 dimerization
and Aβ oligomerization. The level of the Aβ oligomeric band
was highly increased in cells expressing C99 mutated in the
central GXXXG motif (GG29/33LL, referred to as m5) with
respect to cells expressing non-mutated C99, but the size
of the oligomers remained the same (Figure 5B). Strikingly,
the GA38/42LL mutation (referred to as mA) abolished Aβ
oligomer production, and mutations affecting G29XXXG33,
G33XXXG37 and G38XXXA42 motifs (referred to as mB and
mC) produced intermediate levels of oligomers. We analyzed
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FIGURE 3 | Detection of oligomeric bands and measurement of Aβ in the extracellular medium of cells expressing C99 and C42. (A) Culture media of
CHO cells expressing APP, C99, and C42 were analyzed by Western blotting using the W0-2 antibody. The ∼30 kDa oligomer band (∗) detected in culture media
-similar to the one observed in cell lysates- is indicated by an arrow. (B) Soluble monomeric Aβ38, Aβ40, and Aβ42 were quantified by ECLIA in the culture media of
transfected cells. Values (means ± SEM) given in pg/ml are representative of three independent experiments (n = 3 in each experiment). ∗∗∗p < 0.001, ∗p < 0.05, as
compared to control (mock-transfected cells).
FIGURE 4 | Oligomers detected in cells and not re-captured from the culture medium. CHO cells were either transfected by the C42 construct (transfected
cells) or treated (treated cells) for 48 h with the conditioned culture medium of C42-transfected cells (mock, non-transfected), as depicted on the top of the figure.
The cell lysates and culture media of transfected and treated cells were recovered and analyzed by Western blotting with the W0-2 antibody. The ∼30 kDa oligomer
band (∗) detected in cell lysates and culture media is indicated by an arrow.
the contribution to oligomer formation of key G/A residues in
the G29XXXG33/G38XXXA42 motifs. The single G33L mutation
was sufficient to induce the oligomerization profile observed with
m5 (GG23/33LL). In that context (G33L), mutation of small
residues from the G38XXXA42 interface (mB = GG33/38LL and
mC = GA33/42LL) reduced the oligomerization promoted by
the mutation of the critical G33 residue (Figure 5C). We found
that these oligomeric bands did not result from changes in
C99 dimerization (Munter et al., 2007; Kienlen-Campard et al.,
2008; Ben et al., 2012a). Dimerization measured by a highly
sensitive split protein assay (Decock et al., 2015) was found to
be equivalent for C99, C99 m5, and C99 mA (Figures 5D,E),
whereas oligomeric bands are abundant in C99 m5 but not in
C99 mA cell lysates (Figure 5B). Altogether, this indicated that
mutations of glycine residues could play a critical but dual role
in Aβ production, without major changes in overall dimerization
of C99. This idea was further addressed by expressing mutants
of C42 in cells. Identical mutations to those studied in the
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FIGURE 5 | Continued
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FIGURE 5 | Continued
Impact of GXXXG/GXXXA mutations on C99 dimerization and Aβ oligomerization. (A) Schematic representation of human the C99 and C42 constructs
used. Numbering corresponds to amino acid position in the C99 sequence. The amino acid substitutions generated by site-directed mutagenesis are in red. Glycine
and alanine residues of GXXXG/GXXA sequences are underlined. TM, Transmembrane region; ext, extracellular; int, intracellular. (B) Expression of C99 and Aβ
oligomers analyzed in cell lysates by Western blotting with the APP C-terminal antibody and the W0-2 antibody, respectively. Oligomers (∗) and C99 are indicated by
arrows. (C) Expression of C99 and Aβ oligomers analyzed in lysates of cells expressing the different C99 mutants by Western blotting with the W0-2 antibody.
Oligomers (∗) and C99 are indicated by an arrow. (D,E) Dimerization of C99 and C99 mutants (m5, mA) was measured in living cells by the split-luciferase
complementation assay. Cells were transfected with C99-coding sequences fused to two hGLuc moieties (hGluc1 and 2, see Figure 1). Bioluminescence (luciferase
activity) was measured as RLU and given as percentage of bioluminescence detected in cells co-expressing C99-hGLuc1 and C99-hGLuc2. Values (means ± SEM)
are representative of three independent experiments (n = 4 in each experiment). ∗∗∗p < 0.001, n.s. (non-significant), as compared to control (mock-transfected
cells). Expression of the fusion proteins was checked in cell lysates by Western blotting with the hGLuc antibody and the W0-2 antibody. (F) Analysis of Aβ
oligomerization was monitored by Western blotting with the W0-2 antibody in cell lysates or culture media of cells expressing C42 or C42 mutants. Actin was used
as loading probe (cell lysates). Oligomers (∗) are indicated by an arrow.
C99 were introduced in C42 (Figure 5A). Mutation of glycine
residues from the G29XXXG33 and G33XXXG37 motifs, especially
the G33L mutation, strongly increased the production of Aβ
oligomers, which migrated at the same size as C99-derived
oligomers (Figures 5B,C). Mutation of small residues (G/A) of
the G38XXXA42 motif abolished oligomerization (Figure 5F).
Strikingly, the single G38L mutation decreased oligomerization
of C42, and the G38L mutation in the context of G33L (mB)
strongly impaired oligomerization of G33L mutants. On the
other hand, the A42L mutation had moderate effects and was
not able to counteract the increased oligomerization induced
by G33L mutation (mC). The oligomers detected had the
same electrophoretic profile in cell lysates and culture media,
confirming the idea that oligomers are formed in cells and
released into the culture medium. The critical residues for
Aβ oligomerization are G33 and G38. G33L mutation strongly
promotes oligomerization; G38L blocks it with a dominant effect
on G33 residue modification.
Oligomeric Aβ42 Peptides Affect
Neuronal Differentiation
One important question was to understand whether the
oligomers we found to be produced in living cells and released
in the extracellular medium displayed pathological properties.
A growing number of studies indicate that the pathological
properties of Aβ are directly related to the formation of particular
oligomeric assemblies (Benilova et al., 2012). We used the culture
medium of CHO cells transfected with C42, C42m5, and C42mA
to treat neuronal NG108-15 cells when differentiation is induced
(Figure 6A). Culture media recovered from transfected CHO
cells (after 24 h of conditioning) showed the Aβ oligomeric profile
detailed above: oligomeric Aβ was found in C42-expressing cells,
at higher levels in cells expressing C42m5, but not in those
expressing C42mA. All had the same electrophoretic profile.
NG108-15 cells were treated for 5 days with CHO cell medium,
renewed every 48 h. At the end of the treatment, oligomeric
bands of Aβ were readily detectable in medium of treated
NG108-15 cells (Figure 6B). Five days after treatment, control
cells showed the typical neurite outgrowth of differentiated
NG108-15 cells (Stanga et al., 2015) measured by MAP2 staining
(Figures 6C,D). NG108-15 cells treated with medium from C42-
and C42m5-expressing CHO cells showed altered differentiation
and reduced neurite outgrowth. The intensity of MAP2 staining
was particularly reduced in cells treated with media from C42m5-
expressing cells, in which the highest concentration of Aβ
oligomers was detected. In contrast, the differentiation pattern of
cells treated with media of C42mA-expressing cells, in which no
oligomeric Aβ is detected, was comparable to that of non-treated
cells. Thus, differentiation and neurite outgrowth of NG108-15
cells is impaired by the presence of Aβ oligomers. Importantly,
this is not simply linked to cytotoxicity of these oligomers since
the treatments did not affect NG108-15 cell survival in all the
conditions tested (Figure 6E). Together, these data highlight
an intrinsic property of specific Aβ oligomers to disrupt the
formation of a neuronal network, which might be a very early
event in β-amyloid pathologies.
DISCUSSION
Our major findings are as follows: (i) expression of a construct
coding for a peptide corresponding to Aβ42 leads to the
formation of oligomers of 28–30 kDa (with no detection of
monomeric Aβ42) that are resistant to denaturation and display
neuropathological properties; (ii) the same size oligomer can
be detected when C99 (β-CTF) is expressed, but in this case
a monomeric form can also be detected, suggesting that the
location of processing in the cell can influence the extent of
oligomerization; (iii) Aβ40 does not induce the formation of such
oligomeric species; (iv) the oligomers induced by Aβ42 and C99
are similar, and their size remains identical upon mutation; (v)
the formation of oligomers is regulated by the G29XXXG33 and
G38XXXA42 transmembrane motifs – G33 of the G29XXXG33
motifs exerts a negative effect and G38 of the GXXXA motif
exerts a stimulatory effect on oligomer formation; and (vi) the
same motifs also regulate processing of C99 (Kienlen-Campard
et al., 2008) without affecting the extent of C99 dimerization in
cells.
Aβ42 Oligomers Are Formed in Cells
The oligomeric peptides revealed by Western blotting that
were initially thought to be C99 dimers (Kienlen-Campard
et al., 2008) correspond indeed to Aβ42 oligomers. These
Aβ oligomers are produced in cells either by the processing
of the APP amyloidogenic fragment (C99) to Aβ, or when
a peptide corresponding to Aβ42 is expressed in cells.
Strikingly, soluble monomeric Aβ forms are only detected
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FIGURE 6 | Continued
Effects of Aβ oligomers on neuronal cell differentiation and survival. (A) Neuronal NG108-15 cells were treated with media of control CHO cells (mock) or
CHO cells transfected with C42, C42 mutant 5 (m5) or C42 mutant A (mA) during the differentiation process. (B) The presence of Aβ oligomers in the media of CHO
producing cells and NG108-15 cells (at day 5) was assessed by Western blotting with the W0-2 antibody. Oligomers (∗) are indicated by arrows. (C) Neuronal
differentiation was assessed by immunostaining of NG108-15 treated cells with the MAP2 antibody. Nuclei were stained with the DAPI. Scale: 200 µm.
(D) Quantification of MAP2 immunostaining was performed and expressed as percentage of intensity measured in NG108-15 cells treated with the control medium
(mock). Values (means ± SEM) are representative of three independent experiments (n = 2 in each experiment). ∗∗∗p < 0.0001, ∗∗p < 0.001, ns (non-significant) as
compared to cells treated with the control medium. (E) Survival of the NG108-15 cells was assessed by MTS assay and given as percentage of survival measured in
cells treated with the control medium. Values (means ± SEM) are representative of three independent experiments (n = 3 in each experiment). Statistical analysis
showed non-significant differences between the conditions.
in C99-expressing cells and not when Aβ42 is expressed.
Thus, the maintenance of soluble Aβ42 might depend on
intracellular compartments where C99 fragments are processed.
C42 fragments generate Aβ42 without being processed by
the γ-secretase. We found that C55 fragments containing
the KKK capping motifs at the TM/intracellular junction
become substrates for γ-secretase (Supplementary Figure S4).
This observation is quite intriguing and needs to be further
investigated, but it suggests that monomeric Aβ can only be
produced by specific substrates and in specific compartments,
with the short sequence spanning residues 42–55 being sufficient
to localize it to a compartment productive for γ-secretase
cleavage. As soon as these requirements are met, Aβ shows a
high propensity to aggregate, both in cells and in the supernatant.
When Aβ42 is directly produced in cellular compartments
(C42 constructs), it spontaneously aggregates to form oligomers;
soluble monomeric Aβ is no longer detectable. In this regard,
it remains to be determined whether co-expression of Aβ42
and C99 would allow the detection of soluble Aβ42, would
increase the levels of Aβ42 oligomers or promote formation
of a higher molecular weight oligomer. The Aβ oligomers we
detected are enriched in membrane-bound compartments and
found in cell culture medium in conditions where no cytotoxicity
is readily measured in CHO cells. They are thus secreted
rather than simply released in the extracellular space upon
cell death and subsequent leaking of intracellular components.
In addition, we found that intracellular oligomers are not
recaptured from the culture medium, or at least at very low
levels that cannot be detected in our experimental conditions.
This observation strongly supports the conclusion that Aβ
oligomers are readily formed in cells and further secreted in
the extracellular medium. Intriguingly, only Aβ assemblies of
∼25/30 kDa, corresponding to the expected molecular weight of
Aβ hexamers, can be detected under our experimental conditions.
It does not exclude that other Aβ oligomers are produced by
the cells, but their conformation should in this case not be
stable enough to withstand with the high temperature denaturing
conditions (SDS) we used to run Western blots. The Aβ oligomers
we identified are very stable, resistant to SDS, temperature
(Supplemental Figure S3) and formic acid denaturation (not
shown).
Oligomers were detected only with constructs expressing
Aβ42, and not Aβ40. Aβ42, unlike Aβ40, can form stable
trimeric and tetrameric complexes (Chen and Glabe, 2006) as
well as globulomer structures (dodecamers) in the presence
of SDS (Barghorn et al., 2005), and can form pentamers and
hexamers in solution (Bitan et al., 2003; Bernstein et al.,
2009). SDS was suggested to artificially produce stable Aβ
assemblies. We found Aβ oligomers in the culture media that
were not isolated by SDS-based extraction, suggesting that they
are not generated by a spurious effect of the detergent. One
obvious question is to understand how such Aβ42 oligomers
can assemble in cells. Previous studies showed that low-
temperature and low-salt conditions can stabilize disk-shaped
oligomers (Ahmed et al., 2010). They do not have the β-sheet
structure characteristic of fibrils, but are rather composed
of loosely aggregated strands. Importantly, it has recently
been shown that at physiological temperature (37◦C) and at
high concentration, Aβ42 rapidly aggregates into unstructured
specific oligomers (Fu et al., 2015). The high concentrations
achieved here by direct expression of Aβ42 could indeed mimic
pathological situation in which Aβ accumulates in specific
cellular compartments.
G33 and G38 Residues from G29XXXG33
and G38XXXA42 Motifs Dramatically
Affect the Aβ Oligomerization Process
Small amino acid residues (G/A) present in GXXXG or GXXXA
motifs are known to promote TM helix association. Their
mutation was shown to strongly affect the processing of the
β-CTF (Munter et al., 2007; Kienlen-Campard et al., 2008).
Using a protein fragment complementation assay based on
Gaussia princeps luciferase, we show that the effects on C99
dimerization of mutating the G29XXXG33 and G38XXXA42
motifs are not major. While these motifs might change the
precise interface of dimers, they do not control the overall
extent of dimerization, at least when measured by the proximity
of the C-terminal ends. These results are in line with our
recently published work (Decock et al., 2015) showing that
the intracellular domain of C99 has a dominant influence
on C99 dimerization. GXXXG motifs present in APP TM
region might regulate processing of amyloidogenic CTFs either
independently of dimerization or by controlling precise dimeric
conformations.
We showed that mutation of these glycine residues indeed
dramatically affected the formation of Aβ oligomers. G33 and
G38 play a predominant role in this process by promoting
or blocking oligomerization, respectively. They belong to two
different motifs composed of small residues G/A separated by
three aminoacids, with G38 being like a pivot. Importantly,
identical Aβ oligomers were detected in cells expressing mutated
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or non-mutated C99 or C42. For the GXXXG mutants, high
amounts of oligomers were detected, but no soluble monomeric
Aβ is measured by ECLIA. Soluble monomeric Aβ was not
detected for the different GXXXA mutants, but the mutations
in these constructs are at positions preventing detection by
the C-terminal ECLIA capture antibody. Our results would
suggest that soluble monomeric Aβ is produced by the different
mutants, but that the mutations shift the monomeric-oligomeric
Aβ equilibrium toward the formation of oligomeric Aβ forms
(G33 mutants), or block the conversion from monomers to
oligomers (G38 mutants). The turn in the Aβ structure at G38 is
a characteristic of Aβ42 oligomers and molecular contacts have
been reported in the monomeric unit of Aβ42 fibrils between
G38 and F19 (Luhrs et al., 2005) and between M35 and A42
(Masuda et al., 2008). The particular roles of G38 and A42 could
first explain the low oligomerization profile of Aβ produced
from C99mA and C42mA in which both G38 and A42 are
mutated, and the absence of oligomer formation with Aβ40
lacking the A42 position. G38 is important to form a solvent
accessible turn in the β-hairpin structure of the Aβ42 building
blocks assembled in oligomers. G38 to L mutation could thus
break the conformation of Aβ monomers which promotes the
formation of oligomers as proposed by Ahmed et al. (2010).
G33 residue is part of the G33LMVG37 hydrophobic sequence
forming a β-strand which is critical for the Aβ monomers to
adopt an antiparallel β-hairpin structure present in Aβ oligomers
prior to conversion to β-sheet structure. Mutation of G33 is
thus very likely to modify Aβ conformation in a way that favors
oligomerization. Our results are in line with previous studies
highlighting G33 as critical for the generation of Aβ42 assemblies
(Harmeier et al., 2009). Mutation of G33 was suggested to
promote rapid Aβ oligomerization by conformational changes
favoring the formation of high molecular weight oligomers.
However, these observations await further structural studies in
order to clearly understand how G33 and G38 can contribute
to Aβ oligomerization in opposite ways as we observed in
cells.
Aβ42 Oligomers Produced by Cells
Display Neuropathological Properties
Emerging evidence indicates that Aβ oligomers, and not Aβ
fibrils, have neuropathological properties. Aβ oligomers can
rapidly interact with cell membranes and display neurotoxic
effects, before a further possible conversion to protofibrils
or fibrils (Ahmed et al., 2010). Apart from cytotoxic effects,
Aβ oligomers have been shown to cause various neuronal
dysfunctions. Accumulation of soluble (non-fibrillar) Aβ forms
is correlated with the progression of AD (McLean et al., 1999)
and is a predictor of synaptic changes and disruption of neuronal
circuits occurring in the pathology (Hsia et al., 1999; Lue
et al., 1999). We showed here that Aβ oligomers released in
the cell medium strongly impair neuronal differentiation and
neurite outgrowth, but did not display significant neurotoxicity.
The neurotoxic effect of Aβ42 was reported to depend on
its intraneuronal accumulation (Kienlen-Campard and Octave,
2002; Bayer and Wirths, 2010), but this is restricted to neurons or
primary neuron cultures and does not occur in cell lines (Kienlen-
Campard et al., 2002). Interestingly, we observed intracellular
accumulation of Aβ oligomers in cell lines (CHO) without
observing cytotoxic effects. It is very likely that Aβ-related
cytotoxicity takes place in differentiated post-mitotic neurons,
by specific yet poorly understood mechanisms that could
involve autophagy. It would be therefore of particular interest
to further address Aβ42 oligomer formation, distribution and
cytotoxicity in neurons or neuronal cultures. More specifically,
it would be useful to decipher in neuronal model if the toxicity
related to intracellular Aβ accumulation involves oligomers, and
the precise mechanisms underlying the pathological properties
of extracellular Aβ assemblies. Our results do not exclude
that long-time exposure to Aβ oligomers we identified could
trigger toxic effects per se. One could also imagine that
pathological effects of Aβ oligomers involve specific receptors,
among which APP itself (Lorenzo et al., 2000). This could
be evaluated in APP deficient (KO) mice models (Heber
et al., 2000). All these processes, which need to be further
elaborated, could be highly relevant for sporadic Alzheimer’s
disease where with age the capacity to maintain soluble Aβ
decreases and Aβ42 accumulates in neurons as an early
event. Previous studies have shown that Aβ concentrated by
more than two orders of magnitude can reach micromolar
concentrations in acidic vesicular compartments (Hu et al.,
2009). This local high increase in Aβ concentration could
initiate oligomerization in these compartments. Together these
observations provide a strong impetus to address the formation
and precise subcellular localization of Aβ oligomers in neurons,
and to analyze whether and how they are related to neuronal
dysfunction.
However, the fact that Aβ oligomers did not induce cytotoxic
effects, but strongly impaired neurite outgrowth and maturation
of the neuronal network is in line with previous observations.
The extracellular accumulation of a 56-kDa soluble Aβ oligomer,
isolated from brain of AD transgenic mice, impaired memory
independently of any neuronal loss (Lesne et al., 2006). It would
be of particular interest to investigate if oligomers identical to
the ones we identified here can be isolated from transgenic AD
mice or brains of AD patients. The role of these oligomers on
the formation of neurofibrillary tangles (NFTs), another key AD
lesion, should also be addressed. Indeed, amyloid deposition
has been shown to dramatically aggravate tauopathy in AD
mice models (Stancu et al., 2014). It is also important to
note that neuronal-specific mechanisms, like post-translational
modifications, can participate in Aβ oligomerization. For
instance, phosphorylation at different positions, including Ser8
and Ser26, have been shown to enhance or block the formation of
Aβ oligomers in brains (Kumar et al., 2011, 2013). Whether these
neuronal mechanisms regulate the Aβ assemblies we identified
here should be further explored. Up until now, a puzzling list of
Aβ oligomer species supposed to be multimers of a fundamental
Aβ trimer assembly (hexamers, nonamers, and dodecamers) have
been identified from various experimental systems (including
human AD brains and brains of AD transgenic mice) and
isolated under different experimental conditions (Benilova
et al., 2012). Still, they provide no clear evidence as to
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which are pathologically relevant, and the molecular mechanisms
underlying their precise assembly are poorly understood.
CONCLUSION
We reported here that specific Aβ oligomeric forms can be
produced in living cells, and secreted into the extracellular
medium. Such Aβ assemblies are stable, resistant to temperature
and SDS denaturation, and impair neuronal maturation and
differentiation. They are detected when Aβ is generated upon
C99 processing, and are identified at high levels when Aβ42,
but not Aβ40, is directly expressed in cells. We found two
glycine residues, G33 and G38, to be critical in Aβ assembly
into this oligomer form. Mutation of G33 dramatically increases
Aβ oligomerization, whereas mutation of G38 impairs it. These
observations suggest a protective role and a triggering role for
G33 and G38 in the Aβ oligomerization process, respectively,
and are in line with previous studies highlighting the important
role of the G38 in the Aβ strand-turn-strand conformation
specifically observed in oligomers. In conclusion, our data
provide experimental evidence that Aβ oligomers observed
in vitro are readily produced in membranes of living cells, and
prompt further investigation into their precise structure, how
they assemble, and their pathological relevance to human disease.
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FIGURE S1 |Expression of C40 and C42 mA do not lead to Aβ oligomers
formation. Cells were transfected with the control empty vector (mock), or
constructs expressing C42 or C40. (A) Analysis of C42/C40 expression and
Aβ oligomerization was monitored in cell lysates by Western blotting with the
W0-2 antibody. Oligomers (∗) are indicated by arrows. (B) Expression of C42
and C40 mRNA levels were measured by RTqPCR with the same primers and
given as percentage of mRNA levels measured in C42-expressing cells.
FIGURE S2 | Mass spectrometry analysis of the oligomeric bands
produced in C42-expressing cells. Cell lysates from non-transfected (mock)
and C42 transfected cell were separated on NuPage gradient gels in denaturating
conditions. Gel bands around 30 kDa were excised and proteins were extracted
and digested with trypsin. Following digestion, purified peptide samples were
analyzed by nanoLC coupled to tandem mass spectrometry (MS/MS). The raw
MS file were analyzed and searched against the APP protein sequence database.
The results summarized showed the high confidence identification of two peptide
sequences contained in the C42/Aβ42 peptides. C42 and Aβ42 sequences are
given on the top of the tables. Peptide sequences identified are in bold. Signal
peptide sequence is in blue.
FIGURE S3 | Resistance of Aβ oligomers to temperature. Media of cells
expressing C42 or C42m5 were collected and heated at 95◦C for 0, 10 to 30 min
prior to Western blotting revealed with the W0-2 antibody. Oligomers (∗) are
indicated by an arrow.
FIGURE S4 | Aβ oligomers formation in cells expressing different
C-terminal truncations of C99. (A) Schematic representation of the different
constructs. C99 corresponds to the APP β C-terminal fragment. Numbering
corresponds to aminoacid position in the C99 sequence. C55, C49, and C42
have been generated by entering a stop codon at positions 55, 49, and 42 of
C99, respectively. TM, Transmembrane region; ext, extracellular; int, intracellular.
The aminoacid substitution (referred to as m5) generated for each construct
appears in bold and red. (B) Expression of C99, C99 m5, C45 m5, C49 m5, and
C55 m5 in CHO cells analyzed by Western blotting with the W0-2 antibody.
Oligomers (∗) and monomers are indicated by arrows. (C) Aβ 38, 40, and 42 were
quantified by ECLIA in the culture media of transfected cells. Values
(means ± SEM) given in pg/ml are representative of three independent
experiments (n = 3 in each experiment). ∗p < 0.05, ∗∗∗p < 0.001, as compared
to control cells (mock-transfected cells).
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